Skip to main content
padlock icon - secure page this page is secure

Spectral and Molecular Modeling Studies on the Influence of β-Cyclodextrin and Its Derivatives on Albendazole and Its Anti-Proliferative Activity Against Pancreatic Cancer Cells

Buy Article:

$106.81 + tax (Refund Policy)

Albendazole is a benzimidazole derivative with a broad spectrum of activity against human and animal helminthes parasites. It also exhibits potent anticancer activity against hepatocellular, colorectal and ovarian cancers. Major limitation of Albendazole in its therapeutic use as anticancer agent has been its poor aqueous solubility (0.2 μg/ml in water at 25 °C). Consequently, it is poorly absorbed from the gastrointestinal tract (<5%) resulting in poor bioavailability and different approaches have been investigated to overcome this handicap. In the present study, we describe inclusion complexes of Albendazole with β-cyclodextrin and two of its modified derivatives, viz. hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin (Captisol®) prepared by kneading, microwave irradiation and spray drying methods and characterized by Spectroscopy (FTIR), powder X-ray diffraction (XRD) and differential scanning calorimetry (DSC). The solubilizing effects and interactions of Albendazole with cyclodextrins (CDs) were investigated using phase solubility and NMR studies which indicated that Captisol has a high affinity for the drug and forms inclusion complex having 1:1 molar ratio. This was also observed in the computer simulations and binding energies calculated by the MM-PBSA method. Among the preparative methods spray drying technique was found to be more useful in yielding faster drug dissolution and enhanced aqueous solubility. The water soluble cyclodextrin complexes of Albendazole exhibited higher anti-proliferative activities in dose and time dependent manner against pancreatic cancer cells. The complexes also inhibited colony formation, down-regulated cell cycle marker proteins cylinD1 and c-Myc as well as expression of cancer promoting genes COX-2, VEGF and HIF-1 respectively.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: March 1, 2017

More about this publication?
  • Journal of Pharmaceutical Sciences and Pharmacology is being launched to address the disconnect among different research areas related to pharmaceutical sciences and pharmacology. The extreme specialization has resulted in compartmentalization and complete segregation of disciplines related to pharmaceutical sciences. Relating a new development in drug delivery has become difficult to be noticed by the researchers in other related disciplines like the pharmacologists and/or clinicians. The aim of this journal is to publish high quality original research work and broad reviews in all related disciplines relevant to drugs under the same umbrella. Our expectation is that it will help the researchers, scholars and scientists to put their and others' work in the bigger context resulting in enhanced interdisciplinary and integrated research effort. The journal is intended to cover all disciplines and challenges in science, technology and engineering that contribute to the development of new improved drug molecules and their uses including pharmaceutical aspects.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more